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Cause for Concern?*Gregg W. Stone, MD,y Juan F. Granada, MDzSEE PAGE 1901T he absence of clinical restenosis in the ﬁrstmajor trial of metallic drug-eluting stents(DES) (1) elicited unbridled enthusiasm
among interventional cardiologists. However, it did
not take long to realize that, although DES were a
marked improvement over bare-metal stents (2),
they were not perfect. Speciﬁcally, McFadden and
et al. (3) reported a new complication in 4 patients,
late stent thrombosis occurring after discontinuation
of dual antiplatelet therapy (DAPT) (3). Since then,
we have learned that target lesion-related failures
after 1 year (including restenosis as well as throm-
bosis) occur at a frequency of 2% to 3% per year
for all permanent metallic stents, a rate that may
continue for 20 years or longer (4,5). The mecha-
nisms contributing to these stent-related failures
are multifactorial and include incomplete endotheli-
alization, persistent inﬂammation, vessel straight-
ening and compliance mismatch, strut fracture,
neoatherosclerosis, and others. Bioresorbable vas-
cular scaffolds (BVS), which provide the mechanical
support and drug elution capability of metallic DES
for the ﬁrst 12 months post-implantation and then
completely resorb over several years, were devel-
oped to improve long-term outcomes after coronary
intervention.*Editorials published in the Journal of the American College of Cardiology
reﬂect the views of the authors and do not necessarily represent the
views of JACC or the American College of Cardiology.
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through the Skirball Center for Innovation.The presentation in this issue of the Journal of
4 cases of very late scaffold thrombosis (VLScT),
occurring >1 year after implantation of the Absorb BVS
(Abbott Vascular, Santa Clara, California) (6), may
thus raise eyebrows if not outright concerns of “déjà
vu.” The greatest incremental effects of BVS on
improving very late outcomes, however, are likely to
be shown after their complete resorption, which
occurs in w3 years for the poly(L-lactide) (PLLA)
Absorb scaffold in healthy porcine coronary arteries
(7). Three of the 4 cases reported by Räber et al. (6)
occurred before that time period, so perhaps the out-
comes are not too surprising. The fourth case at 44
months demonstrates that BVS will not eliminate very
late adverse events. What additional insights may be
gleaned from these 4 cases?First, optical coherence tomography (OCT) showed
uncovered struts apposed to the vessel wall were
detected in all cases (range: 2.6% to 8.0%) and were
associated with adherent thrombus. Although a causal
relationship between uncovered stent struts and very
late thrombosis after metallic DES has never been
demonstrated, incomplete endothelialization at the
treated lesion site due to drug and/or persistent
polymer effects may underlie some cases of very late
thrombosis after both metallic DES and polymeric
BVS.
Second, the apparent detection of PLLA-like mate-
rial at 44 months raises questions concerning the time
course and variability of Absorb scaffold resorption in
humans and its potential role in VLScT. In porcine
models, PLLA levels in coronary artery tissue
measured using gel permeation high-pressure liquid
chromatography fall below the limit of quantiﬁcation
(<3% of the original weight) within 3 years (7).
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1916Similarly, intravascular ultrasound-based vessel wall
echogenicity progressively declines over this period,
along with the scaffold’s molecular weight (8). OCT-
deﬁned “preserved boxes” at 3 years are rarely seen
in this model, correlating with histological evidence
of polymer resorption (9). Thus, whereas the presence
of preserved boxes in the 3 reported VLScT cases
occurring within 24 months is not surprising, their
persistence in the case that thrombosed at 44 months
might not have been expected. Is the PLLA resorption
rate the same in humans as in swine, and do the pre-
served boxes still contain PLLA, as opposed to cellular
or connective tissue? Although it is difﬁcult to address
these questions directly in humans, polymer degra-
dation is driven by a hydrothermal process (i.e.,
dependent on water concentration and temperature)
and is independent of other cellular and enzymatic
processes occurring outside the polymer boundaries.
It is possible that extracellular matrix and cellular
components may ﬁll the voids left behind following
PLLA resorption, leading to a similar preserved box
conﬁguration on OCT. In the present report, the
presence of PLLA-like material in Fourier transform
infrared spectroscopy (FTIR) at 44 months in a single
case is suggestive but not deﬁnitive evidence of its
presence, as other biological materials and catheter
components may share a similar FTIR ﬁngerprint.
However, the fact that small zones of birefringence
were evident in the thrombus aspirate makes it
probable that PLLA-like material was present, perhaps
in a protected crystalline form with somewhat
delayed temporal absorption. However, the amount of
PLLA recovered was very small, likely below the level
of quantiﬁcation by current analytical techniques, and
is unlikely to have contributed to the VLScT event.
Third, cases 1, 2, and 4 of the present report suggest
a novel mechanism of VLScT not seen with metallic
DES, that of intraluminal scaffold dismantling (ILSD).
Natural dismantling of the scaffold architecture by
bulk erosion, ﬁrst with interruption of the hoops
between the scaffold rings occurring as early as
6 months, is integral to the beneﬁts seen with BVS.
This process allows return of cyclic pulsatility and
vasomotion, restoration of native vessel curvature,
and expansive remodeling (7). Serial OCT imaging has
demonstrated that late scaffold discontinuities are
common but rarely associated with clinical adverse
events (10). Such natural “fractures,” if mechanically
restrained by neointimal tissue, do not abut into
the lumen and are of no clinical consequence.
Conversely, scaffold dismantling with macroscopic
space-occupying structures protruding into the lumen
(such as with ILSD) may occur either at the time
of implantation (excessive polymer stretching orelongation at break [usually by use of a balloon $0.75
mm larger than the nominal diameter in the case of
Absorb]), or at any time due to excessive biomechan-
ical cyclic stress (high bending forces) or iatrogenic
causes (disruption by interventional catheters of
an already friable device undergoing biodegradation),
in cases without a well-formed neointima. Thus,
although it is conceivable that ILSD may have
contributed to VLScT in the present report, it is also
possible that passage of OCT and thrombus aspiration
catheters may have caused scaffold disruption. The
implications of this phenomenon are that caution is
warranted when passing devices through the BVS
within several years after implantation (immediately
withdrawing the catheter if resistance is felt) and
that prolonged DAPT, if ILSD is visualized, be
considered, at least in patients at low risk for
bleeding. Re-stenting with a metallic DES may also be
appropriate in severe cases of ILSD.
Fourth and ﬁnally, small lumen scaffold areas
were evident in all 4 VLScT cases, which suggests
either suboptimal scaffold expansion at the time
of implantation or structural biomechanical failure
occurring during the process of scaffold resorption
(e.g., ILSD). Lack of serial imaging in these patients
limits our ability to further ascertain the mechanism
of these observations. However, the BVS visually
appear under-expanded in all 4 cases, as conﬁrmed
by the residual angiographic diameter stenosis
ranging from 18.6% to 26.7%. Careful lesion prepa-
ration (pre-dilation) and optimal scaffold expansion
(post-dilation with noncompliant balloons at high
pressure) are required to maximize lumen gain with
ﬁrst-generation BVS. A small minimal stent area is
the most important determinant of late thrombosis,
at least for metallic stents (11) and would be expected
to be even more important for thicker strut ﬁrst-
generation BVS. Conversely, acute strut malap-
position has never been shown to be related to
metallic stent thrombosis, as long as the stent area is
sufﬁcient (11). Further studies are required to deter-
mine whether this holds for BVS as well.
In conclusion, the clinical report by Räber et al. (6),
although only a retrospective collection of a small
number of cases, provides useful insight into the
possible causes of very late device failures among
patients receiving ﬁrst-generation BVS technology.
Some of these mechanisms appear to be similar to
those for metallic DES. However, the present report
also suggests that ILSD may be a novel cause of very
late BVS thrombosis. Conversely, longitudinal stent
deformation and late strut fractures of metallic DES
are occasional causes of very late stent thrombosis
that BVS may reduce (12,13). There are also many
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1917unknowns. For example, given continuous exposure
to lipid and cellular trafﬁcking throughout the
resorption process, will neoatherosclerosis (an
important cause of very late thrombosis after metallic
DES) be less common with BVS (14)? Most impor-
tantly, the denominator of BVS implants without
VLScT during the study period was not reported, and
the fact that “only” 4 such cases have surfaced may
alternatively be considered reassuring. Whether BVSs
do indeed reduce very late thrombotic (and
restenotic) events compared to metallic DES can only
be addressed by large-scale, adequately powered
randomized studies, such as the ongoing ABSORB IVtrial (Absorb IV Randomized Controlled Trial [ABSORB
IV]; NCT02173379). Moreover, BVS technologies will
continue to evolve with the development of thinner
strut platforms with enhanced biomechanical perfor-
mance. Thus, at the present time we should not be
“concerned” about VLScT after BVS—but we should be
“aware!”
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